Advertisement
U.S. markets closed
  • S&P 500

    5,254.35
    +5.86 (+0.11%)
     
  • Dow 30

    39,807.37
    +47.29 (+0.12%)
     
  • Nasdaq

    16,379.46
    -20.06 (-0.12%)
     
  • Russell 2000

    2,124.55
    +10.20 (+0.48%)
     
  • Crude Oil

    83.11
    -0.06 (-0.07%)
     
  • Gold

    2,254.80
    +16.40 (+0.73%)
     
  • Silver

    25.10
    +0.18 (+0.74%)
     
  • EUR/USD

    1.0778
    -0.0015 (-0.14%)
     
  • 10-Yr Bond

    4.2060
    +0.0100 (+0.24%)
     
  • GBP/USD

    1.2621
    -0.0001 (-0.01%)
     
  • USD/JPY

    151.3350
    -0.0370 (-0.02%)
     
  • Bitcoin USD

    70,347.05
    +575.92 (+0.83%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,952.62
    +20.64 (+0.26%)
     
  • Nikkei 225

    40,357.58
    +189.51 (+0.47%)
     

Agenus' Combo Therapy Trial Shows Higher Responses In Cervical Cancer

  • Agenus Inc (NASDAQ: AGEN) presented final results from the Bal/Zal combination study at the European Society for Medical Oncology (ESMO21) Virtual Conference 2021.

  • Related: Agenus Gains As Balstilimab US Application Accepted For Review In Cervical Cancer.

  • The Phase 2 trial evaluated the combination of Balstilimab and zalifrelimab in patients with recurrent/metastatic (R/M) cervical cancer (CC).

  • In the 125 evaluable patients, the overall objective response rate (ORR) was 26%, with 9% of patients achieving a complete response and 17% of patients achieving a partial response.

  • The median duration of response (DoR) was not reached after a 19.4-month median follow-up.

  • Notably, responses were observed in the PD-L1 negative and adenocarcinoma populations, with 9% of both patient groups achieving an ORR.

  • Based on these observations, the Company predicts that more than half of the patients will be alive beyond 12 months.

  • The Bal/Zal combination continued to show no unexpected toxicities, and no new safety signals were identified.

  • Furthermore, later in 2021, Agenus expects to present new data on next-generation CTLA-4 inhibitor AGEN1181.

  • Price Action: AGEN stock is up 4.85% at $5.84 during the premarket session on the last check Friday.

  • Check out our coverage of the European Society for Medical Oncology Congress (ESMO21).

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Advertisement